Promoted Content
Promoted Content

Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Sanofi

              • Deals

              Virtual BoothSanofi Active Ingredient Solutions cover both APIs sales & CDMO.

              FRANCE France

              Contact Supplier Contact Supplier

              Virtual Booth Virtual Booth

              2ND EUROPEAN HEALTHTECH CEO FORUM

              Participation Not Confirmed

              Update your events

              LTL Pharma to Take Over Sanofi’s Diregura in Japan

              Contact the Supplier

              Lead Product(s): Fexofenadine Hydrochloride,Pseudoephedrine

              Therapeutic Area: Immunology Product Name: Diregura

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: LTL Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration August 04, 2020

              Details:

              LTL Pharma will take over the Japanese marketing authorization (MA) of Sanofi’s anti-allergic medicine Diregura (fexofenadine + pseudoephedrine).

              Ethypharm

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              FRANCE France

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              2ND EUROPEAN HEALTHTECH CEO FORUM

              Participation Not Confirmed

              Update your events

              Medexus Enters into Exclusive License to Register and Commercialize Triamcinolone Hexacetonide (TH) in the United States with Ethypharm

              Contact the Supplier

              Lead Product(s): Triamcinolone Acetonide

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Medexus Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement December 18, 2020

              Details:

              Triamcinolone Hexacetonide is a longest-acting corticosteroid for intra articular injection. The companies have agreed to a small upfront fee along with milestone payments at the time of FDA approval, at commercial product launch, and upon certain sales milestones.

              PharmaCompass__DigitalAd